Loading clinical trials...

Influence of Fampridine on Working Memory in Healthy Subjects | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Influence of Fampridine on Working Memory in Healthy Subjects

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects

NCT04516603•Prof. Dominique de Quervain, MD

View on ClinicalTrials.gov

Summary

Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants. The hypotheses is that fampridine improves working memory performance.

Eligibility

Age

18 - 30 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•male or female
•generally healthy
•normotensive (BP between 90/60 mmHg and 140/90 mmHg)
•BMI between 19 and 29,9 kg/m2
•aged between 18 and 30 years
•fluent German-speaking
•Informed consent as documented by signature

Exclusion Criteria

•contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine
•use of potassium channel blockers within the last 3 months
•concomitant treatment with OCT 2 inhibitors (e.g. cimetidine, propranolol)
•acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency)
•acute cerebrovascular condition
•history of seizures
•risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse)
•renal impairment
•history of malignant cancers
•walking problems (e.g. due to dizziness)
+11 more criteria

Locations (1)

University of Basel, Transfaculty Research Platform

Basel, Canton of Basel-City, Switzerland

Key Dates

Start Date

January 1, 2040

Primary Completion Date

December 31, 2041

Completion Date

December 31, 2041

Last Updated

December 5, 2024

Conditions

Working Memory

Interventions

Fampridine SR

DRUG

Placebo

DRUG

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

NCT06751784

Working MemoryMild to Moderate Depression

View study

ACTIVE_NOT_RECRUITING

Cognitive Changes After Major Joint Replacement - Full Trial (Cognigram 2)

NCT03147937

Postoperative Cognitive DysfunctionCognitive Impairment+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Influence of Fampridine on Working Memory in Healthy Subjects

Inclusion Criteria

Exclusion Criteria

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Cognitive Changes After Major Joint Replacement - Full Trial (Cognigram 2)

Induction and Stabilization of Gamma Oscillations With 40 Hz External Brain Stimulation

Improving Neurodevelopment in Adolescents With Congenital Heart Disease

Cognitive Changes After Major Joint Replacement

Working Memory Training in Children With Cerebral Palsy, a Pilot Study